Floatz logo

Atezolizumab

HER2 Negative

TransThera Sciences (Nanjing), Inc.monoclonal_antibodyPhase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

191 Active assets in the HER2 Negative cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Inno-206
Roswell Park Cancer Institute
Phase 3BB
Docetaxel
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 2/3BB

View all 50 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
bladder transitional cell carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →